clinical trial · NCT07405970
A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus
Beijing Mabworks Biotech Co., Ltd.·phase3·recruiting·n = 316
Systemic Lupus ErythematosusMIL62Placebo
brief summary
This study will evaluate the efficacy and safety of MIL62 compared with placebo in participants with systemic lupus erythematosus.
started
Apr 10, 2026
primary completion
Dec 1, 2028
completion
Dec 1, 2028
last updated
May 5, 2026
official title
A Phase 3 Clinical Study to Evaluate the Safety and Efficacy of Recombinant Humanized Monoclonal Antibody MIL62 Injection in the Treatment of Systemic Lupus Erythematosus.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol